Navigation Links
Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that several members of management will speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing.  The conference is taking place May 8-11, 2011 at the Toronto Convention Center.  

  • James Levine, President and Chief Executive Officer, will make opening remarks at a plenary breakfast, What Consumers and Manufacturers Need from Industrial Biotech Companies: A Customer Perspective on Tuesday, May 10th at 7:00 am.
  • Janet Roemer, Chief Operating Officer, will be moderating a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, on Wednesday, May 11th at 11:00 am. Roemer will also be speaking on a panel, The Power of Enzymes, Tuesday, May 10th at 3:00 pm
  • Ken Barrett, Vice President, Business Development, will be moderating a panel, Protein Engineering and Screening Methods, Tuesday, May 10th at 9:00 am.
  • David Weiner, Ph.D., Vice President, R&D Strategy and Partnerships, will be speaking on a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, Wednesday, May 11th at 11:00 am.

  • The Company will also have a booth at space 316 in the Toronto Convention Center.

    For more information on the BIO Industrial Biotechnology Conference please visit http://www.bio.org/worldcongress/index.asp

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

    Vice President, Corporate Communications

    858-431-8580

    kelly.lindenboom@verenium.com

    Sarah Carmody

    Manager, Corporate Communications

    858-431-8581

    sarah.carmody@verenium.com
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2017)... Properties (NYSE: CUZ ) announced today that Amgen, ... 10-year, approximately 125,000 square-foot lease at Corporate Center, a 1,224,000 ... submarket of Tampa, FL. ... for their new location in Tampa ," ... of Cousins Properties. "Amgen is a cutting-edge global company at ...
    (Date:3/27/2017)... DUBLIN , March 27, 2017 ... access to a comprehensive library of reports on Valero ... the transportation fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... is biofuel production to go green. Ethanol today, even though ...
    (Date:3/27/2017)... NEW YORK , March 27, 2017 /PRNewswire/ ... company developing novel therapies for neurodegenerative diseases, including ... confirmation that its application to list the Company,s ... been approved by The NASDAQ Stock Market, a ... of the listing, Neurotrope will ring the Opening Bell ...
    (Date:3/24/2017)... 24, 2017 On Thursday, March ... at 5,817.69, down 0.07%; the Dow Jones Industrial Average ... S&P 500 closed at 2,345.96, marginally dropping 0.11%. US ... in green, 4 sectors finished in red, and 1 ... has initiated reports coverage on the following Biotechnology equities: ...
    Breaking Biology Technology:
    (Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
    (Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
    (Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
    Breaking Biology News(10 mins):